Cocrystal Pharma, Inc. (COCP) is a clinical-stage biotechnology company dedicated to discovering and developing groundbreaking antiviral therapeutics. We focus on combatting serious and chronic viral diseases by targeting the replication process of coronavirus strains (including SARS-CoV-2), influenza viruses, noroviruses, and hepatitis C viruses.

With our unique structure-based drug discovery technology platform and expertise from Nobel Prize-winning scientists, we strive to create exceptional antiviral medications that are both first- and best-in-class. Our core competencies and decade of experience in the field of antiviral therapeutics allow us to actively address the global COVID-19 pandemic, as well as seasonal influenza outbreaks. Understanding the urgent need for effective and safe antiviral treatments, we are rapidly advancing multiple therapeutic candidates designed to efficiently combat viral infections.

Alongside this, we are tirelessly working on discovering and developing antiviral compounds for other high-value indications. Our commitment to innovation and patient well-being drives us as we continue to revolutionize antiviral therapeutics. Join us on this journey to a healthier and virus-free future.

(Note: The provided text did not mention the specific products or services offered by Cocrystal Pharma. Thus, the description focuses on the company's mission, expertise, and dedication to developing antiviral therapeutics. )